Warning letter
Sanapac Co., Inc.: warning letter of Mar 24, 2017
FDA warning letter 514139 · Philadelphia District Office
Key facts
| Reference number | 514139 |
|---|---|
| Company | Sanapac Co., Inc. |
| Subject | CGMP/Dietary Supplement/Adulterated/Misbranded |
| Issue date | Mar 24, 2017 |
| Posted date | Apr 4, 2017 |
| Issuing office | Philadelphia District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 101.4, 101.36, 111, 111.8, 111.55, 111.65, 111.70, 111.103, 111.105, 111.255, 111.453, 101.4(h)(1) and 16 more |
| Inspection city | Dallas |
| Inspection ZIP | 18612 |
| Inspection start date | Nov 28, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: